

References

- 1 Hinuma Y, Nagata K, Hanaoka M *et al*. Adult T-cell leukemia: antigen in an ATL cell line and detection of antibodies to the antigen in human sera. *Proc Natl Acad Sci USA* 1981; **78**: 6476–80.
- 2 Poesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. *Proc Natl Acad Sci USA* 1980; **77**: 7415–9.
- 3 Tajima K. The 4th nation-wide study of adult T-cell leukemia/lymphoma (ATL) in Japan: estimates of risk of ATL and its geographical and clinical features. The T- and B-cell Malignancy Study Group. *Int J Cancer* 1990; **45**: 237–43.
- 4 Uchiyama T. Human T cell leukemia virus type I (HTLV-I) and human diseases. *Annu Rev Immunol* 1997; **15**: 15–37.
- 5 Osame M, Usuku K, Izumo S *et al*. HTLV-I associated myelopathy, a new clinical entity. *Lancet* 1986; **1**: 1031–2.
- 6 Gessain A, Barin F, Vernant JC *et al*. Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. *Lancet* 1985; **2**: 407–10.
- 7 Mochizuki M, Watanabe T, Yamaguchi K *et al*. Uveitis associated with human T-cell lymphotropic virus type I. *Am J Ophthalmol* 1992; **114**: 123–9.
- 8 Nishioka K, Maruyama I, Sato K, Kitajima I, Nakajima Y, Osame M. Chronic inflammatory arthropathy associated with HTLV-I. *Lancet* 1989; **1**: 441.
- 9 Utsunomiya A, Miyazaki Y, Takatsuka Y *et al*. Improved outcome of adult T cell leukemia/lymphoma with allogeneic hematopoietic stem cell transplantation. *Bone Marrow Transplant* 2001; **27**: 15–20.
- 10 Okamura J, Utsunomiya A, Tanosaki R *et al*. Allogeneic stem-cell transplantation with reduced conditioning intensity as a novel immunotherapy and antiviral therapy for adult T-cell leukemia/lymphoma. *Blood* 2005; **105**: 4143–5.
- 11 Yamamoto K, Utsunomiya A, Tobinai K *et al*. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. *J Clin Oncol* 2010; **28**: 1591–8.
- 12 Hermine O, Allard I, Levy V, Arnulf B, Gessain A, Bazarbachi A. A prospective phase II clinical trial with the use of zidovudine and interferon-alpha in the acute and lymphoma forms of adult T-cell leukemia/lymphoma. *Hematol J* 2002; **3**: 276–82.
- 13 Yoshida M. Multiple viral strategies of HTLV-I for dysregulation of cell growth control. *Annu Rev Immunol* 2001; **19**: 475–96.
- 14 Grassmann R, Aboud M, Jeang KT. Molecular mechanisms of cellular transformation by HTLV-I Tax. *Oncogene* 2005; **24**: 5976–85.
- 15 Jeang KT, Giam CZ, Majone F, Aboud M. Life, death, and tax: role of HTLV-I oncoprotein in genetic instability and cellular transformation. *J Biol Chem* 2004; **279**: 31991–4.
- 16 Matsuoka M, Jeang KT. Human T-cell leukaemia virus type I (HTLV-I) infectivity and cellular transformation. *Nat Rev Cancer* 2007; **7**: 270–80.
- 17 Kannagi M, Sugamura K, Kinoshita K, Uchino H, Hinuma Y. Specific cytolysis of fresh tumor cells by an autologous killer T cell line derived from an adult T cell leukemia/lymphoma patient. *J Immunol* 1984; **133**: 1037–41.
- 18 Jacobson S, Shida H, McFarlin DE, Fauci AS, Koenig S. Circulating CD8+ cytotoxic T lymphocytes specific for HTLV-I pX in patients with HTLV-I associated neurological disease. *Nature* 1990; **348**: 245–8.
- 19 Arnulf B, Thorel M, Poirot Y *et al*. Loss of the *ex vivo* but not the reinducible CD8+ T-cell response to Tax in human T-cell leukemia virus type I-infected patients with adult T-cell leukemia/lymphoma. *Leukemia* 2004; **18**: 126–32.
- 20 Kato H, Koya Y, Ohashi T *et al*. Oral administration of human T-cell leukemia virus type I induces immune unresponsiveness with persistent infection in adult rats. *J Virol* 1998; **72**: 7289–93.
- 21 Hasegawa A, Ohashi T, Hanabuchi S *et al*. Expansion of human T-cell leukemia virus type I (HTLV-I) reservoir in orally infected rats: inverse correlation with HTLV-I-specific cellular immune response. *J Virol* 2003; **77**: 2956–63.
- 22 Kannagi M, Harashina N, Kurihara K *et al*. Tumor immunity against adult T-cell leukemia. *Cancer Sci* 2005; **96**: 249–55.
- 23 Jacobson S. Human T lymphotropic virus, type-I myelopathy: an immunopathologically mediated chronic progressive disease of the central nervous system. *Curr Opin Neurol* 1995; **8**: 179–83.
- 24 Osame M. Pathological mechanisms of human T-cell lymphotropic virus type I-associated myelopathy (HAM/TSP). *J Neurovirol* 2002; **8**: 359–64.
- 25 Jeffery KJ, Usuku K, Hall SE *et al*. HLA alleles determine human T-lymphotropic virus-I (HTLV-I) proviral load and the risk of HTLV-I-associated myelopathy. *Proc Natl Acad Sci USA* 1999; **96**: 3848–53.
- 26 Bangham CR, Osame M. Cellular immune response to HTLV-I. *Oncogene* 2005; **24**: 6035–46.
- 27 Akimoto M, Kozako T, Sawada T *et al*. Anti-HTLV-I tax antibody and tax-specific cytotoxic T lymphocyte are associated with a reduction in HTLV-I proviral load in asymptomatic carriers. *J Med Virol* 2007; **79**: 977–86.
- 28 Kubota R, Kawanishi T, Matsubara H, Manns A, Jacobson S. HTLV-I specific IFN-gamma+ CD8+ lymphocytes correlate with the proviral load in peripheral blood of infected individuals. *J Neuroimmunol* 2000; **102**: 208–15.
- 29 Kinoshita T, Shimoyama M, Tobinai K *et al*. Detection of mRNA for the tax1/rex1 gene of human T-cell leukemia virus type I in fresh peripheral blood mononuclear cells of adult T-cell leukemia patients and viral carriers by using the polymerase chain reaction. *Proc Natl Acad Sci USA* 1989; **86**: 5620–4.
- 30 Fujisawa J, Seiki M, Kiyokawa T, Yoshida M. Functional activation of the long terminal repeat of human T-cell leukemia virus type I by a trans-acting factor. *Proc Natl Acad Sci USA* 1985; **82**: 2277–81.
- 31 Newbound GC, O'Rourke JP, Collins ND, Andrews JM, DeWille J, Lairmore MD. Repression of tax-mediated human t-lymphotropic virus type I transcription by inducible cAMP early repressor (ICER) protein in peripheral blood mononuclear cells. *J Med Virol* 2000; **62**: 286–92.
- 32 Jiang S, Inada T, Tanaka M, Furuta RA, Shingu K, Fujisawa J. Involvement of TORC2, a CREB co-activator, in the *in vivo*-specific transcriptional control of HTLV-I. *Retirovirology* 2009; **6**: 73.
- 33 Satou Y, Yasunaga J, Yoshida M, Matsuoka M. HTLV-I basic leucine zipper factor gene mRNA supports proliferation of adult T cell leukemia cells. *Proc Natl Acad Sci USA* 2006; **103**: 720–5.
- 34 Kinpara S, Hasegawa A, Utsunomiya A *et al*. Stromal cell-mediated suppression of human T-cell leukemia virus type I expression *in vitro* and *in vivo* by type I interferon. *J Virol* 2009; **83**: 5101–8.
- 35 Kannagi M, Sugamura K, Sato H, Okochi K, Uchino H, Hinuma Y. Establishment of human cytotoxic T cell lines specific for human adult T cell leukemia virus-bearing cells. *J Immunol* 1983; **130**: 2942–6.
- 36 Parker CE, Daenke S, Nightingale S, Bangham CR. Activated, HTLV-I-specific cytotoxic T-lymphocytes are found in healthy seropositives as well as in patients with tropical spastic paraparesis. *Virology* 1992; **188**: 628–36.
- 37 Kannagi M, Harada S, Maruyama I *et al*. Predominant recognition of human T cell leukemia virus type I (HTLV-I) pX gene products by human CD8+ cytotoxic T cells directed against HTLV-I-infected cells. *Int Immunol* 1991; **3**: 761–7.
- 38 Goon PK, Igakura T, Hanon E *et al*. Human T cell lymphotropic virus type I (HTLV-I)-specific CD4+ T cells: immunodominance hierarchy and preferential infection with HTLV-I. *J Immunol* 2004; **172**: 1735–43.
- 39 Elovaara I, Koenig S, Brewah AY, Woods RM, Lehky T, Jacobson S. High human T cell lymphotropic virus type I (HTLV-I)-specific precursor cytotoxic T lymphocyte frequencies in patients with HTLV-I-associated neurological disease. *J Exp Med* 1993; **177**: 1567–73.
- 40 Pique C, Ureta-Vidal A, Gessain A *et al*. Evidence for the chronic *in vivo* production of human T cell leukemia virus type I Rof and Tof proteins from cytotoxic T lymphocytes directed against viral peptides. *J Exp Med* 2000; **191**: 567–72.
- 41 Macnamara A, Rowan A, Hilburn S *et al*. HLA class I binding of HBZ determines outcome in HTLV-I infection. *PLoS Pathog* 2010; **6**: e1001117.
- 42 Asquith B, Mosley AJ, Barfield A *et al*. A functional CD8+ cell assay reveals individual variation in CD8+ cell antiviral efficacy and explains differences in human T-lymphotropic virus type I proviral load. *J Gen Virol* 2005; **86**: 1515–23.
- 43 Komori K, Hasegawa A, Kurihara K *et al*. Reduction of human T-cell leukemia virus type I (HTLV-I) proviral loads in rats orally infected with HTLV-I by reimmunization with HTLV-I-infected cells. *J Virol* 2006; **80**: 7375–81.
- 44 Ohashi T, Hanabuchi S, Kato H *et al*. Prevention of adult T-cell leukemia-like lymphoproliferative disease in rats by adoptively transferred T cells from a donor immunized with human T-cell leukemia virus type I Tax-coding DNA vaccine. *J Virol* 2000; **74**: 9610–6.
- 45 Hanabuchi S, Ohashi T, Koya Y *et al*. Regression of human T-cell leukemia virus type I (HTLV-I)-associated lymphomas in a rat model: peptide-induced T-cell immunity. *J Natl Cancer Inst* 2001; **93**: 1775–83.
- 46 Kawano N, Shimoda K, Ishikawa F *et al*. Adult T-cell leukemia development from a human T-cell leukemia virus type I carrier after a living-donor liver transplantation. *Transplantation* 2006; **82**: 840–3.
- 47 Suzuki S, Uozumi K, Maeda M *et al*. Adult T-cell leukemia in a liver transplant recipient that did not progress after onset of graft rejection. *Int J Hematol* 2006; **83**: 429–32.
- 48 Harashina N, Kurihara K, Utsunomiya A *et al*. Graft-versus-Tax response in adult T-cell leukemia patients after hematopoietic stem cell transplantation. *Cancer Res* 2004; **64**: 391–9.
- 49 Kaplan JE, Osame M, Kubota H *et al*. The risk of development of HTLV-I-associated myelopathy/tropical spastic paraparesis among persons infected with HTLV-I. *J Acquir Immune Defic Syndr* 1990; **3**: 1096–101.
- 50 Hisada M, Okayama A, Shioiri S, Spiegelman DL, Stuver SO, Mueller NE. Risk factors for adult T-cell leukemia among carriers of human T-lymphotropic virus type I. *Blood* 1998; **92**: 3557–61.
- 51 Iwanaga M, Watanabe T, Utsunomiya A *et al*. Human T-cell leukemia virus type I (HTLV-I) proviral load and disease progression in asymptomatic

- HTLV-I carriers: a nationwide prospective study in Japan. *Blood* 2010; **116**: 1211–9.
- 52 Nagai M, Usuku K, Matsumoto W *et al.* Analysis of HTLV-I proviral load in 202 HAM/TSP patients and 243 asymptomatic HTLV-I carriers: high proviral load strongly predisposes to HAM/TSP. *J Neurovirol* 1998; **4**: 586–93.
- 53 Shimizu Y, Takamori A, Utsunomiya A *et al.* Impaired Tax-specific T-cell responses with insufficient control of HTLV-I in a subgroup of individuals at asymptomatic and smoldering stages. *Cancer Sci* 2009; **100**: 481–9.
- 54 Wodarz D, Nowak MA, Bangham CR. The dynamics of HTLV-I and the CTL response. *Immunol Today* 1999; **20**: 220–7.
- 55 Toulza F, Heaps A, Tanaka Y, Taylor GP, Bangham CR. High frequency of CD4+ FoxP3+ cells in HTLV-I infection: inverse correlation with HTLV-I-specific CTL response. *Blood* 2008; **111**: 5047–53.
- 56 Azakami K, Sato T, Araya N *et al.* Severe loss of invariant NKT cells exhibiting anti-HTLV-I activity in patients with HTLV-I-associated disorders. *Blood* 2009; **114**: 3208–15.
- 57 Harashima N, Tanosaki R, Shimizu Y *et al.* Identification of two new HLA-A*1101-restricted tax epitopes recognized by cytotoxic T lymphocytes in an adult T-cell leukemia patient after hematopoietic stem cell transplantation. *J Virol* 2005; **79**: 10088–92.
- 58 Yamano Y, Nagai M, Brennan M *et al.* Correlation of human T-cell lymphotropic virus type I (HTLV-I) mRNA with proviral DNA load, virus-specific CD8(+) T cells, and disease severity in HTLV-I-associated myelopathy (HAM/TSP). *Blood* 2002; **99**: 88–94.
- 59 Hasui K, Utsunomiya A, Izumo S *et al.* An immunohistochemical analysis of peripheral blood tissue specimens from leukemia cells: Leukemic cells of Adult T-cell leukemia/lymphoma express p40Tax protein of human T-cell lymphotropic virus type I when entering proliferation. *Acta Histochem Cytochem* 2003; **36**: 345–52.
- 60 Hinuma Y, Gotoh Y, Sugamura K *et al.* A retrovirus associated with human adult T-cell leukemia: *in vitro* activation. *Gann* 1982; **73**: 341–4.
- 61 Umadome H, Uchiyama T, Hori T *et al.* Close association between interleukin 2 receptor mRNA expression and human T cell leukemia/lymphoma virus type I viral RNA expression in short-term cultured leukemic cells from adult T cell leukemia patients. *J Clin Invest* 1988; **81**: 52–61.
- 62 Kurihara K, Harashima N, Hanabuchi S *et al.* Potential immunogenicity of adult T cell leukemia cells *in vivo*. *Int J Cancer* 2005; **114**: 257–67.
- 63 Takeda S, Maeda M, Morikawa S *et al.* Genetic and epigenetic inactivation of tax gene in adult T-cell leukemia cells. *Int J Cancer* 2004; **109**: 559–67.
- 64 Tamiya S, Matsuoka M, Etoh K *et al.* Two types of defective human T-lymphotropic virus type I provirus in adult T-cell leukemia. *Blood* 1996; **88**: 3065–73.
- 65 Koiwa T, Hamano-Usami A, Ishida T *et al.* 5'-long terminal repeat-selective CpG methylation of latent human T-cell leukemia virus type I provirus *in vitro* and *in vivo*. *J Virol* 2002; **76**: 9389–97.
- 66 Hanon E, Hall S, Taylor GP *et al.* Abundant tax protein expression in CD4+ T cells infected with human T-cell lymphotropic virus type I (HTLV-I) is prevented by cytotoxic T lymphocytes. *Blood* 2000; **95**: 1386–92.
- 67 Sodroski J, Rosen C, Goh WC, Haseltine W. A transcriptional activator protein encoded by the x-lor region of the human T-cell leukemia virus. *Science* 1985; **228**: 1430–4.
- 68 Nagai K, Jinnai I, Hata T *et al.* Adhesion-dependent growth of primary adult T cell leukemia cells with down-regulation of HTLV-I p40Tax protein: a novel *in vitro* model of the growth of acute ATL cells. *Int J Hematol* 2008; **88**: 551–64.
- 69 Hishizawa M, Imada K, Kitawaki T, Ueda M, Kadowaki N, Uchiyama T. Depletion and impaired interferon-alpha-producing capacity of blood plasmacytoid dendritic cells in human T-cell leukaemia virus type I-infected individuals. *Br J Haematol* 2004; **125**: 568–75.
- 70 Jones KS, Petrow-Sadowski C, Huang YK, Bertolette DC, Ruscetti FW. Cell-free HTLV-1 infects dendritic cells leading to transmission and transformation of CD4(+) T cells. *Nat Med* 2008; **14**: 429–36.
- 71 Colisson R, Barblu L, Gras C *et al.* Free HTLV-I induces TLR7-dependent innate immune response and TRAIL relocalization in killer plasmacytoid dendritic cells. *Blood* 2010; **115**: 2177–85.
- 72 Miyatake Y, Ikeda H, Ishizu A *et al.* Role of neuronal interferon-gamma in the development of myelopathy in rats infected with human T-cell leukemia virus type I. *Am J Pathol* 2006; **169**: 189–99.
- 73 Iwakura Y, Tosu M, Yoshida E *et al.* Induction of inflammatory arthropathy resembling rheumatoid arthritis in mice transgenic for HTLV-I. *Science* 1991; **253**: 1026–8.
- 74 Medzhitov R, Janeway CA Jr. Innate immunity: impact on the adaptive immune response. *Curr Opin Immunol* 1997; **9**: 4–9.
- 75 Boasso A, Shearer GM. Chronic innate immune activation as a cause of HIV-1 immunopathogenesis. *Clin Immunol* 2008; **126**: 235–42.
- 76 Nomura M, Ohashi T, Nishikawa K *et al.* Repression of tax expression is associated both with resistance of human T-cell leukemia virus type I-infected T cells to killing by tax-specific cytotoxic T lymphocytes and with impaired tumorigenicity in a rat model. *J Virol* 2004; **78**: 3827–36.
- 77 Meekings KN, Leipzig J, Bushman FD, Taylor GP, Bangham CR. HTLV-I integration into transcriptionally active genomic regions is associated with proviral expression and with HAM/TSP. *PLoS Pathog* 2008; **4**: e1000027.
- 78 Tomaru U, Ikeda H, Ohya O *et al.* Human T lymphocyte virus type I-induced myeloneuropathy in rats: implication of local activation of the pX and tumor necrosis factor-alpha genes in pathogenesis. *J Infect Dis* 1996; **174**: 318–23.
- 79 Olieri S, Hernandez E, Lezin A *et al.* HTLV-I Evades Type I Interferon Antiviral Signaling by Inducing the Suppressor of Cytokine Signaling 1 (SOCS1). *PLoS Pathog* 2010; **6**: e1001177.



RESEARCH

Open Access

Functional impairment of Tax-specific but not cytomegalovirus-specific CD8⁺ T lymphocytes in a minor population of asymptomatic human T-cell leukemia virus type 1-carriers

Ayako Takamori¹, Atsuhiko Hasegawa^{1*}, Atae Utsunomiya², Yasuhiro Maeda^{3,9}, Yoshihisa Yamano⁴, Masato Masuda⁵, Yukiko Shimizu⁴, Yotaro Tamai¹, Amane Sasada¹, Na Zeng¹, Ilseung Choi⁶, Naokuni Uike⁶, Jun Okamura⁷, Toshiki Watanabe⁸, Takao Masuda¹ and Mari Kannagi¹

Abstract

Background: Human T-cell leukemia virus type 1 (HTLV-1) causes adult T-cell leukemia (ATL) and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in a small percentage of infected individuals. ATL is often associated with general immune suppression and an impaired HTLV-1-specific T-cell response, an important host defense system. We previously found that a small fraction of asymptomatic HTLV-1-carriers (AC) already showed impaired T-cell responses against the major target antigen, Tax. However, it is unclear whether the impaired HTLV-1 Tax-specific T-cell response in these individuals is an HTLV-1-specific phenomenon, or merely reflects general immune suppression. In this study, in order to characterize the impaired HTLV-1-specific T-cell response, we investigated the function of Tax-specific CD8⁺ T-cells in various clinical status of HTLV-1 infection.

Results: By using tetramers consisting of HLA-A*0201, -A*2402, or -A*1101, and corresponding Tax epitope peptides, we detected Tax-specific CD8⁺ T-cells in the peripheral blood from 87.0% of ACs (n = 20/23) and 100% of HAM/TSP patients (n = 18/18) tested. We also detected Tax-specific CD8⁺ T-cells in 38.1% of chronic type ATL (cATL) patients (n = 8/21), although its frequencies in peripheral blood CD8⁺ T cells were significantly lower than those of ACs or HAM/TSP patients. Tax-specific CD8⁺ T-cells detected in HAM/TSP patients proliferated well in culture and produced IFN- γ when stimulated with Tax peptides. However, such functions were severely impaired in the Tax-specific CD8⁺ T-cells detected in cATL patients. In ACs, the responses of Tax-specific CD8⁺ T-cells were retained in most cases. However, we found one AC sample whose Tax-specific CD8⁺ T-cells hardly produced IFN- γ , and failed to proliferate and express activation (CD69) and degranulation (CD107a) markers in response to Tax peptide. Importantly, the same AC sample contained cytomegalovirus (CMV) pp65-specific CD8⁺ T-cells that possessed functions upon CMV pp65 peptide stimulation. We further examined additional samples of two smoldering type ATL patients and found that they also showed dysfunctions of Tax-specific but not CMV-specific CD8⁺ T-cells.

Conclusions: These findings indicated that Tax-specific CD8⁺ T-cells were scarce and dysfunctional not only in ATL patients but also in a limited AC population, and that the dysfunction was selective for HTLV-1-specific CD8⁺ T-cells in early stages.

* Correspondence: hase.impt@tmd.ac.jp

¹Department of Immunotherapeutics, Tokyo Medical and Dental University, Tokyo, Japan

Full list of author information is available at the end of the article

Background

Human T-cells leukemia virus type 1 (HTLV-1) is the causative agent of a highly aggressive CD4⁺ T-cell malignancy, adult T-cell leukemia (ATL)[1,2]. As many as 10 million individuals are thought to be infected worldwide, in southern Japan, the Caribbean basin, South America, Melanesia, and equatorial Africa[3]. Unlike human immunodeficiency virus (HIV), the majority of HTLV-1-infected individuals are clinically asymptomatic during their lifetime. However, approximately 5% develop ATL, and another 2-3% develop a variety of chronic inflammatory diseases such as HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP)[4-8].

HTLV-1-specific cytotoxic T-lymphocytes (CTLs) are thought to play a pivotal role in containing the proliferation of HTLV-1-infected T-cells[9,10]. Tax is known to be the dominant target antigen for HTLV-1-specific CTLs[10-13], and a high frequency of Tax-specific CTLs can be detected in HAM/TSP patients and some asymptomatic HTLV-1 carriers (ACs)[10-14]. However, ATL patients show general immune suppression[15], reduced frequency and dysfunction of Tax-specific CTLs[16,17]. Regulatory T cell (Treg)-like function of FoxP3⁺ ATL cells and diminished function of dendritic cells may be involved in the immune suppression in ATL patients [18,19], but the precise mechanism is not yet clarified. We previously demonstrated that a fraction of ACs also exhibit reduced T-cell responses against Tax protein [20]. These observations suggest that the reduced HTLV-1-specific T-cell response might be an underlying risk of ATL development, but not the result of ATL. However, it is unknown how the function of HTLV-1-specific CD8⁺ T-cells becomes impaired in a small percentage of ACs and whether its dysfunction is specific for HTLV-1 antigen or due to general immune suppression.

During chronic stage of infection with several viruses, such as HIV and hepatitis C virus (HCV), virus-specific CTLs gradually lose their cytotoxic activity, the ability to proliferate and secrete a diverse profile of cytokines, ultimately leading to exhaustion, anergy or even deletion of these cells[21-26]. Programmed death-1 (PD-1), a negative regulator in the CD28 superfamily, has recently been shown to be highly expressed on virus-specific T-cells during many chronic viral infections[27-29]. It has also been reported that the interaction of PD-1 with PD-ligand 1 (PD-L1) negatively regulates cytokine production and proliferation of T-cells[30,31]. A previous report indicates that PD-1 is up-regulated on the dominant Tax-specific CTLs in ATL patients and ACs and that immune regulation through the PD-1/PD-L1 pathway may be involved in the dysfunction of HTLV-1-specific CTLs in ATL patients[32].


Studies on memory T-cell differentiation have shown that phenotype, function, and homeostasis of memory T-cells vary for different persistent virus infections[33]. Central memory T-cells (T_{CM}; CD45RA⁻CCR7⁺) are elicited by non-persisting virus that provide transient antigen stimulation, such as in Influenza virus infection. In contrast, effector memory T-cells (T_{EM}; CD45RA⁺CCR7⁻) predominate when relatively high levels of antigen persist, such as in HIV infection. Terminally differentiated memory (T_{Diff}; CD45RA⁺CCR7⁻) can be seen when antigen persists at a low level, such as in cytomegalovirus (CMV) infection. In HTLV-1 infection, it has been reported that dominant Tax-specific CTLs in HAM/TSP patients consist of T_{EM} and T_{Diff} compartments[34].

We previously identified some major epitopes recognized by HTLV-1-specific CTLs in infected individuals carrying HLA-A2, -A11, or -A24[12,35,36]. These allowed us to monitor HTLV-1-specific CTLs and analyze their functions *ex vivo*, by using antigen/HLA tetrameric complexes. In this study, we demonstrate that IFN- γ production and proliferative capacity of tetramer-binding Tax-specific CD8⁺ T-cells were severely impaired not only in ATL patients but also in a minor population of asymptomatic HTLV-1 carriers (ACs). Importantly, the T-cell dysfunction at the asymptomatic stage was selective for HTLV-1 but not for CMV antigen. In addition, severely impaired HTLV-1-specific but not CMV-specific CD8⁺ T-cells responses were also observed in patients diagnosed as smoldering ATL, the clinical condition of which is close to that of AC. The dysfunction of HTLV-1-specific CD8⁺ T-cells in an early clinical stage implies HTLV-1-specific immune suppressive mechanism might be an underlying risk for ATL.

Results

Incidence and frequency of Tax-specific CD8⁺ T-cells in ACs, and HAM/TSP and cATL patients

In 23 ACs and 18 HAM/TSP and 21 cATL patients carrying HLA-A2, -A11 and/or -A24 alleles, we evaluated the frequencies of Tax-specific CD8⁺ T-cells by using cognate Tax/HLA tetramers (Figure 1 and Table 1). Tax-specific CD8⁺ T-cells were detected in 87.0% of ACs and all HAM/TSP patients tested. In contrast, only 38.1% of cATL patients have detectable frequencies of Tax-specific CD8⁺ T-cells (Table 1). Figure 1B shows that the average frequency of Tax-specific CD8⁺ T-cells in the CD8⁺ T-cells of cATL patients (n = 21, 0.90% range: 0%-9.45%) was significantly lower than that in ACs (n = 23, 2.37%, range: 0%-8.23%, *P* = 0.0023). HAM/TSP patients had the highest average frequency of Tax-specific CD8⁺ T-cells among the three groups (n = 18, 8.88%, range: 1.86%-29.9%, *P* = 0.0001; vs. AC, *P* < 0.0001; vs. cATL patients), which is consistent with



previous reports [10,17,37]. It is of note that Tax-specific CD8⁺ T-cells are detectable even in cATL patients, although the frequency is very low.

Impaired cell proliferation and IFN- γ production of Tax-specific CD8⁺ T-cells in cATL but not HAM/TSP patients

We next examined IFN- γ production and cell proliferation of Tax-specific CD8⁺ T-cells in HAM/TSP and cATL patients (Figure 2A). Intracellular IFN- γ staining


showed that Tax-specific CD8⁺ T-cells in all HAM/TSP patients tested produced IFN- γ when stimulated with Tax peptide (Figure 2A). Tax-specific CD8⁺ T-cells in those HAM/TSP patients proliferated regardless of stimulation with Tax peptide (Figure 2B). In contrast to HAM/TSP patients, IFN- γ production from Tax-specific CD8⁺ T-cells in a cATL patient was hardly detectable even when stimulated with Tax peptide (4.8%, Figure 2A). In the same donor, Tax-specific CD8⁺ T-cells

Table 1 The number of blood samples with detectable Tax-specific CD8⁺ T-cells in all samples tested in this study

Tax/HLA tetramers used in this study	Disease Status		
	AC	HAM/TSP	cATL
HLA-A*0201/Tax11-19	12/14 ¹	7/7	2/11
HLA-A*1101/Tax88-96	4/4	4/4	3/5
HLA-A*2402/Tax301-309	13/15	13/13	5/16
No. of tetramer ⁺ samples/total no. of blood samples ²	20/23 (87.0%)	18/18 (100%)	8/21 (38.1%)

¹ No. of samples with detectable Tax-specific CD8⁺ T-cells/total no. of samples carrying each HLA allele. When the frequency of tetramer⁺ cells was more than 0.04% of CD8⁺ T-cells, the sample was regarded as detectable.

² In case Tax-specific CD8⁺ T-cells was detectable by either tetramer in a sample carrying two of three HLA-A alleles above, the sample was regarded as positive.



could be detected in fresh blood (1.32%) and after 6 hrs incubation as shown in Figure 2A, but not after 6 day-culture, suggesting that Tax-specific CD8⁺ T-cells in this cATL patient had no proliferative capacity (Figure 2B). We tested PBMC from four other cATL patients who had detectable Tax-specific CD8⁺ T-cells, but none of them showed proliferation of Tax-specific CD8⁺ T-cells by either the CFSE-based proliferation assay or 13-day culture (Additional file 1). Collectively, these results indicate that Tax-specific CD8⁺ T-cells from most cATL patients are impaired in their capacities to proliferate and produce IFN- γ .

Diversity in the IFN- γ production and cell proliferation of Tax-specific CD8⁺ T-cells in ACs

Our recent studies using the GST-Tax protein-based assay demonstrated that the extent of Tax-specific T-cell responses varied widely in ACs[20]. We then evaluated proliferation and/or IFN- γ production of tetramer-binding Tax-specific CD8⁺ T-cells in 14 ACs (Table 2). Representative data on 4 of 14 ACs are shown in Figures 3A and 3B. In 3 ACs (#251, #313, and #360), Tax-specific CD8⁺ T-cells produced IFN- γ and proliferated in response to Tax peptide (Figures 3A and 3B). Similarly to HAM/TSP samples, a large proportion of Tax-

Table 2 Clinical information and summary for Tax-specific CD8⁺ T cells in 14ACs

ID	Age	Sex	WBC (/μl)	CD4 (%) ¹	CD8 (%) ¹	HLA	Tetramer (%) ²	Functions and phenotype of Tax-specific CD8 ⁺ T-cells ³			Aby (%) ⁷	PVL ⁸
								IFN-γ ⁺ (%) ⁴	CFSE ^{low} (%) ⁵	PD-1 ⁺ (%) ⁶		
#217	70s	F	6800	ND ⁹	5.72	A24	1.94	27.7	78.9	78.7	0	14
#236	30 s	F	6500	ND	11.9	A24	2.54	31.1	0	54.1	0	22
#238	60 s	F	5700	ND	12.7	A11	1.29	36.4	100	0	0	2
#243	50 s	F	4100	ND	24.6	A2/24	0.39/3.67	11.3	27.6	93.8	0	3
#245	40 s	F	5000	ND	22.6	A2	0.73	62.5	75	ND	1	58
#251	60 s	M	4800	ND	11.9	A2/11	0.70/8.23	35.8	84.4	36.7	0	2
#279	40 s	M	6200	34.1	11.6	A2/24	4.70/0.18	12.9	30.8	70.2	1	48
#287	70 s	M	4800	72.5	10.0	A2/24	1.17/0.23	11.1	0	55.6	2	81
#309	60 s	F	4600	37.5	24.8	A11/24	6.88/4.26	51.7	76.2	85.3	1.5	29
#311	60 s	F	3200	30.6	14.8	A2/24	1.02/1.94	51.3	ND	ND	0	6
#312	50 s	F	2700	27.3	36.4	A24	2.03	77.8	ND	ND	ND	UN ¹⁰
#313	60 s	M	7300	25.4	31.0	A24	1.11	55.7	60	90.6	ND	4
#315	50 s	F	7500	26.5	7.9	A2/24	6.88/0	24.5	84.7	20	0.6	17
#360	50 s	M	6200	37.7	29.9	A2	2.6	63.1	68.4	10.2	0	UN

¹The number indicates percentage of CD4⁺ or CD8⁺ T cells in lymphocytes.

²The number indicates percentages of tetramer⁺ cells in CD8⁺ T-cells. Two numbers divided by a slash represent those detected by two different tetramers corresponding to two HLA alleles shown in the HLA column.

³In case of a sample carrying two of three HLA-A alleles (A2, A11, or A24), Tax-specific CTLs predominantly detected by a tetramer were used. The number represents percentage of indicated cells in the tetramer-binding CD8⁺ T cells.

⁴Evaluated by intracellular IFN-γ staining following 6 hours stimulation with corresponding Tax peptide.

⁵Evaluated by CFSE intensities in labeled PBMC after 6 days incubation with corresponding Tax peptide stimulation.

⁶The number represents percentage of indicated PD-1⁺Tax-specific CD8⁺ T cells without culture.

⁷Aby; abnormal lymphocytes

⁸PVL; proviral load. The number represents copy number per 1000 PBMCs.

⁹ND; not determined

¹⁰UN; undetectable

specific CD8⁺ T-cells in these ACs spontaneously proliferated without stimulation with Tax peptide, probably due to viral reactivation in HTLV-1-infected cells *in vitro*[38,39]. IFN-γ production was specifically detected for peptide stimulation, and 35.8-55.7% of Tax-specific CD8⁺ T-cells produced a good amount of IFN-γ (mean fluorescence intensity, MFI: 63.7-195.3) upon stimulation in the samples of #251, #313, and #360. In contrast, Tax-specific CD8⁺ T-cells in one AC (#287) did not proliferate in response to Tax peptide and showed a very weak IFN-γ response with low amounts of IFN-γ (MFI: 37.5) in a low percentage (11.1%) of Tax-specific CD8⁺ T-cells (Figures 3A and 3B). In other ACs (#243 and #279), low frequency of IFN-γ⁺ Tax-specific CD8⁺ T-cells was observed, but the levels of IFN-γ production (MFI: #243; 58.8, #279; 77.6) and the proliferative responses were comparable to other ACs (Table 2). Tax-specific CD8⁺ T-cells in #236 failed to proliferate but showed favorable IFN-γ production (MFI: 80.1) in 31.1% of the cells.

Among AC samples tested, AC#287 carried higher proviral load (81 copies in 1000 PBMCs) than any other ACs (Table 2). Since Tax-specific CD8⁺ T-cells in #287 had severely impaired IFN-γ production and proliferative

potential, we examined the relationship of the function of these T-cells with proviral loads. Both percentages of IFN-γ⁺ and dividing Tax-specific CD8⁺ T-cells among CD8⁺ T-cells were likely to be inversely correlated with proviral loads although they were not statistically significant (Figure 3C and 3D). Because of the limited availability of the samples, we focused mainly on two ACs (#287 and #313) in the studies hereafter.

Dysfunction of Tax-specific CD8⁺ T-cells and inefficient CD8⁺ cell-mediated HTLV-1 control in AC #287

To examine whether Tax-specific CD8⁺ T-cell responses were influenced by activation of antigen-presenting cells (APCs), PBMC from #313 (responder) and #287 (low responder) were stimulated with Tax peptide in the presence or absence of LPS, a potent activator of APCs such as dendritic cells (DCs) and monocytes/macrophages. In #313, the frequency of Tax-specific CD8⁺ T-cells increased from 1.11% to 6.47% or 4.07% at day 13, after stimulation with or without Tax peptide, respectively. The frequency of Tax-specific CD8⁺ T-cells in #313 further increased in the presence of Tax peptide and LPS (15.81%). In contrast to #313, the frequency of Tax-specific CD8⁺ T-cells in #287 decreased from 1.17%




Figure 3 IFN-γ production and cell proliferation of Tax-specific CD8⁺ T-cells in ACs. (A, B) IFN-γ production (A) and cell proliferation (B) of Tax-specific CD8⁺ T-cells in PBMCs from 4 ACs were assessed as in Figure 2. The number given in parenthesis shows mean fluorescence intensity (MFI) of IFN-γ expression in the IFN-γ⁺ tetramer⁺ cells. (C, D) Relation between the percentage of IFN-γ⁺ (C) or dividing (D) Tax-specific CD8⁺ T-cells and proviral loads (PVL) in ACs. Dots represent individual ACs. The Spearman rank correlation test was used to determine correlations and *P* values.

to 0.2% after stimulation with Tax peptide, and was not recovered by LPS stimulation (Figure 4A). In addition, HTLV-1-infected cells have been reported to express C-C chemokine receptor type 4 (CCR4) and have FoxP3⁺ Treg-like function[18,40]. However, the proliferative ability of Tax-specific CD8⁺ T-cells in #287 was not restored even in the absence of CCR4⁺ infected cells (data not shown).

To further examine the function of Tax-specific CD8⁺ T-cells in #313 and #287, we observed the expression of CD69, an early activation marker transiently expressed on T lymphocytes that precedes cytokine secretion after antigenic stimulation, and CD107a, a marker of degranulation associated with cytotoxic activity in an antigen-specific manner[41]. CD69 was up-regulated on Tax-specific CD8⁺ T-cells in #313 when stimulated with Tax peptide, but not in #287, which was in agreement with their abilities to produce IFN- γ (Figure 4B). In #313, 22.4% of Tax-specific CD8⁺ T-cells mobilized CD107a to the surface during a 6-hr culture with Tax peptide stimulation, while CD107a surface expression was detected on 4% of Tax-specific CD8⁺ T-cells in the culture without stimulation (Figure 4C). However, no CD107a mobilization was detected on the surface of Tax-specific CD8⁺ T-cells in #287 with or without Tax peptide stimulation (Figure 4C). These results indicate that HTLV-1-specific CD8⁺ T-cells in AC #287 did not properly activate upon antigen stimulation, and therefore failed to control HTLV-1-infected cells.

The Tax/HLA tetramers used in this study allow us to evaluate the functions of CD8⁺ T-cells only against an immunodominant epitope, Tax. We therefore compared HTLV-1 Gag p19 in the culture between whole and CD8⁺ cell-depleted PBMCs to examine the role of total HTLV-1-specific CD8⁺ T-cells including the dominant Tax-specific CD8⁺ T-cells, in suppression of HTLV-1 production from infected cells (Figure 4D). As expected, depletion of CD8⁺ cells from PBMCs in #313 led to significantly higher HTLV-1 production compared to whole PBMCs ($P = 0.0115$). In contrast, HTLV-1 p19 production increased only a little in the culture of CD8⁺ cell-depleted PBMCs in #287 ($P = 0.1563$), indicating that HTLV-1-specific CD8⁺ T-cells other than the dominant Tax-specific CD8⁺ T-cells might have a reduced ability to control the infected cells in this donor. It is of note that HTLV-1-infected cells from both two donors carried intact HTLV-1 proviral genomic DNA because HTLV-1 p19 could be detected after 7 day-culture.

Phenotypic analysis of functional and dysfunctional Tax-specific CD8⁺ T-cells

We next characterized the differentiation status of memory T-cells in Tax-specific CD8⁺ T-cells. Human

CD8 T-cells may be classified as naïve T-cells (CD45RA⁺CCR7⁺CD27⁺), T_{CM} (CD45RA⁺CCR7⁺CD27⁺), T_{EM} (CD45RA⁺CCR7⁻CD27⁺), and T_{Diff} (CD45RA⁺CCR7⁻CD27⁻) cells[42-44]. As shown in Figure 5A, almost all Tax-specific CD8⁺ T-cells in both #313 and #287 were skewed to CD45RA⁺CCR7⁻CD27⁺ T_{EM} cells, and there was no essential difference between two donors.

A previous report has shown that PD-1 was highly up-regulated on Tax-specific CD8⁺ T-cells in ATL patients and ACs[32]. We therefore examined PD-1 expression on Tax-specific CD8⁺ T-cells in several AC samples, including #287. The frequency of PD-1⁺ Tax-specific CD8⁺ T-cells was very high in #309 (85.3%) and #313 (96%) (Figure 5B and Table 2) while those Tax-specific CD8⁺ T-cells retained the proliferative and the cytokine-producing abilities (Figure 3A and Table 2). In #287, the frequency of PD-1-expressing Tax-specific CD8⁺ T-cells (55.6%) was lower than #309 and #313, but higher than that of PD-1⁺ CMVpp65-specific CD8⁺ T-cells in the same donor (Figure 5B). The levels of PD-1 expression showed a similar tendency to the frequency of PD-1⁺ T-cells. In addition, the blockade of PD-1/PD-ligand 1 (PD-L1) pathway did not restore the proliferative capacity of Tax-specific CD8⁺ T-cells in #287 (data not shown).

Conserved functions of CMV-specific CD8⁺ T-cells in #287

We next examined whether the impairment of proliferative capacity and effector functions observed in #287 CD8⁺ T-cells were specific for HTLV-1 antigens or the result of general immune suppression. PBMC from #287 contained CMVpp65-specific CD8⁺ T-cells (2.3% of CD8⁺ T-cells), as detected by tetramer staining. The frequency of CMVpp65-specific CD8⁺ T-cells increased from 2.3% to 66.0% following in vitro CMVpp65 peptide stimulation, but not without the peptide stimulation (Figure 6A). Antigen-specific IFN- γ and CD69 expression were clearly detected in CMVpp65-specific CD8⁺ T-cells in #287 (Figures 6B and 6C). Furthermore, CMVpp65-specific CD8⁺ T-cells mobilized CD107a to the surface in response to CMVpp65 peptide (Figure 6D). These results demonstrate that in #287, CMVpp65-specific CD8⁺ T-cells, but not Tax-specific CD8⁺ T-cells, have proliferative potential and effector functions, such as cytotoxic activity and IFN- γ release, suggesting that the impaired CD8⁺ T-cell function in #287 was specific for HTLV-1.

Dysfunction of Tax-specific but not CMVpp65-specific CD8⁺ T-cells also in sATL patients

Finally, we extended the study to see whether patients with early stage ATL might exhibit similar dysfunction selective for HTLV-1-specific CD8⁺ T-cells. We found two smoldering ATL (sATL) patients (#110 and #353)





Figure 4 Dysfunction of Tax-specific CD8⁺ T-cells and inefficient CD8⁺ cell-mediated HTLV-1 control in AC#287. (A) For antigen-specific T-cell proliferation, PBMCs from #313 and #287 were cultured for 13 days with or without Tax peptide in the presence or absence of 0.1 μg/ml LPS. The number indicates the percentage of tetramer⁺ cells in CD8⁺ T-cells. (B, C) PBMCs were stimulated with or without 10 μM Tax peptide for 6 hrs. The expression of CD69 (B) and CD107a (C) in Tax-specific CD8⁺ T-cells was analyzed by flow cytometry. (B) Bar indicates the percentage of CD69⁺ cells in Tax-specific CD8⁺ T-cells. (C) The number represents the percentage of CD107a⁺ cells in Tax-specific CD8⁺ T-cells. (D) Whole PBMCs and CD8-depleted fractions in ACs (#287 and #313) were cultured for 7 days and HTLV-1 p19 in the supernatants were measured by HTLV-1 p19 ELISA. *P* value was determined by the unpaired *t* test.




possessing 6.89% and 3.15% of tetramer-binding Tax-specific CD8⁺ T-cells, respectively. The sATL patient #353 carried 5% of abnormal lymphocytes (ably) with a normal range of lymphocyte number, whose status is very close to the borderline with ACs. Patient #110 carried 4% of abnormal lymphocytes with mild lymphocytosis. Tax-specific CD8⁺ T-cells of two sATL patients (#110 and #353) did not proliferate in response to Tax peptides as similarly observed in a cATL patient (#224) (Figure 7A) and most other cATL patients (Figure 2A and Additional file 1). In contrast, CMVpp65-specific CD8⁺ T-cells in both sATL patients vigorously proliferated when stimulated with CMVpp65 peptides. CMVpp65-specific CD8⁺ T-cells in a cATL (#224) also proliferated, but to a lesser degree, which might reflect general immune suppression in this patient (Figure 7).

Discussion


In this study, we detected Tax-specific CD8⁺ T-cells in 87%, but not the rest of ACs tested, by using tetramers

containing Tax major epitope-peptides presented by HLA-A*0201, A*1101, and A*2402. Tax-specific CD8⁺ T-cells were also detected in 38% of cATL patients, but at reduced frequencies and with severely impaired functions. Further analysis of Tax-specific CD8⁺ T-cells in 14 ACs indicated that they were functional in most of ACs tested except one (#287), whose Tax-specific CD8⁺ T-cells poorly responded to specific peptides. However, CMVpp65-specific CD8⁺ T-cells of this individual were fully functional. Similar T-cell dysfunction selective for HTLV-1, but not CMV, was also observed in sATL patients, one of which (#353) had no clinical symptoms but 5% abnormal lymphocytes. General immune suppression might partly account for the scarcity and/or the dysfunction of Tax-specific CD8⁺ T-cells in ATL patients, but not those in the AC or the sATL patients as they were selective for HTLV-1. These findings suggest that HTLV-1-specific immune suppression is undergoing in a minor group of ACs and an early stage of ATL.



The presence of tetramer-binding Tax-specific CD8⁺ T-cells in cATL patients, although at low frequencies, implies that they have encountered antigen during the chronic phase of ATL disease, suggesting that Tax may be expressed *in vivo*. This may be supported by a previous report showing that virus-specific CD8⁺ T-cells fails to acquire memory T-cell property of long-term antigen-independent persistence during chronic lymphocytic choriomeningitis virus (LCMV) infection[45]. However, there is no direct evidence that infected cells produce Tax in infected individuals. HTLV-1-specific T-cell responses in cATL patients are largely different

from HAM/TSP patients. In HAM/TSP patients, Tax-specific CD8⁺ T-cells proliferated vigorously and a large population of them produced IFN-γ. In contrast, the function of Tax-specific CD8⁺ T-cells in cATL patients was profoundly suppressed, similarly to tumor infiltrating lymphocytes (TIL)[46]. In cATL patients, Tax-specific CD8⁺ T-cells that were detected before culture decreased in number to undetectable or very low levels after 6 days, regardless of peptide stimulation (data not shown). This is not likely to be due to TCR down-regulation, because TCRs on Tax-specific CD8⁺ T-cells in HAM/TSP patients are down-regulated on days 1 to 4



and reappeared by day 6 in vitro[34]. Moreover, we could not observe any tetramer⁺ CD8⁺ T-cells even in the 13-day culture (data not shown), suggesting these cells might have died during the culture.

Severe dysfunction of Tax-specific CD8⁺ T-cells was observed not only in cATL patients, but also in an AC #287. Fresh PBMCs of #287 contained 1.17% tetramer⁺ cells in the CD8⁺ T-cell fraction. However, none of these tetramer-positive T-cells proliferated in culture, with or without Tax peptide stimulation (Figure 3B). Although a few populations of them (11.1%) produced a small amount of IFN- γ , they lacked degranulation activity for cytotoxicity or expression of CD69, an early activation marker, upon specific stimulation (Figures 3 and 4). Importantly, CMVpp65-specific CD8⁺ T-cells in the same donor were clearly activated, and exhibited these characteristics upon stimulation with pp65 peptides (Figure 6). These observations indicated that the impaired Tax-specific CD8⁺ T-cells function in #287 was not attributable to general immune suppression, but to an HTLV-1-specific phenomenon. In addition, CD8-depletion study indicated that not only the dominant Tax-specific CD8⁺ T-cell function but also other HTLV-1-specific CD8⁺ T cell responses might be reduced in #287 (Figure 4D). Since CMV-specific CD8⁺ T-cells responded well to the specific peptides, antigen-presenting cells in culture were not likely to be responsible for the selective suppression of Tax-specific CD8⁺ T-cells.

In addition, it has been shown that HTLV-1-infected cells generally express CCR4 and have Treg-like function[18,40]. However, depletion of CCR4⁺ cells did not restore the proliferative ability of Tax-specific CD8⁺ T-cells (data not shown), indicating that suppression of the infected cells were not likely to be the major reason for the impaired Tax-specific CD8⁺ T-cell function in our culture system. These observations suggest that in #287, Tax-specific CD8⁺ T-cells themselves might lose their functions.

Many chronic viral infections affect the phenotype, function, and maintenance of memory T-cells [24,42,47,48]. T_{EM} cells predominate in infections in which relatively high levels of antigen persist and continuous antigen stimulation are required for maintenance of T_{EM} cells. As described in HAM/TSP patients [34], Tax-specific CD8⁺ T-cells in both ACs (#287 and #313) were primarily enriched in T_{EM} memory pool in spite of the functionality of Tax-specific CD8⁺ T-cells (Figure 5A), which may support continuous or periodical expression of viral antigen in vivo during an asymptomatic stage.

PD-1 is known to play a major role in regulating T-cell exhaustion during chronic infection. In this study, we could not obtain any data supporting the involvement of PD-1 in the dysfunction of Tax-specific CD8⁺ T-cells. However, we observed that Tax-specific CD8⁺ T-cells in some ACs showed IFN- γ production, but not

proliferative capacity (Table 2). This partially lacked function of Tax-specific CD8⁺ T-cells is similar to the features of T-cell exhaustion. Whether Tax-specific CD8⁺ T-cells are exhausted in HTLV-1 infection, and whether other molecules associated with T-cell exhaustion are involved in the impairment of Tax-specific CD8⁺ T-cell responses are necessary to be clarified because some inhibitory molecules such as T-cell immunoglobulin and mucin domain-containing protein-3 (TIM-3), lymphocyte activated gene-3 (LAG-3), and transcription factors including BLIMP-1 are also found to be associated with T-cell exhaustion [49].

The incidence of Tax-specific CD8⁺ T-cell detection was high (87.0%) in ACs. Given the fact that the incidence of Tax-specific CD8⁺ T-cells in HAM/TSP patients was 100%, a small fraction of ACs lacking detectable tetramer-binding cells might lack Tax-specific T-cell responses. Our previous study investigating GST-Tax protein-based T-cell responses supports this notion [20]. In the present study, even in ACs possessing Tax-specific CD8⁺ T-cells, at least one individual exhibited T-cell dysfunction selectively for HTLV-1. The incidence of tetramer-positive cells was reduced in ATL patients (38.1%), and the function of these cells was impaired in all the ATL patients even with detectable tetramer-binding Tax-specific CD8⁺ T-cells. Our findings suggest that HTLV-1-specific T-cell responses are selectively impaired in a small percentage of HTLV-1-infected individuals in the asymptomatic stages, and the proportion of individuals with such characteristics increase as the stages proceed towards ATL. Strategies to reactivate HTLV-1-specific T-cells at early stages might contribute to a reduction in the immunological risk of ATL.

Conclusions

Tax-specific CD8⁺ T-cells were scarce and dysfunctional in a limited AC population and ATL patients, and the dysfunction of CD8⁺ T-cells was selective for HTLV-1 in early stages. These results implied the presence of some HTLV-1-specific T-cell suppressive mechanisms even in asymptomatic stages, which are not a result of general immune suppression in ATL but could be underlying conditions toward disease progression.

Methods

Samples

Blood samples from 64 HTLV-1-seropositive individuals were used in this study: 23 asymptomatic carriers (ACs), 18 HAM/TSP patients, 2 smoldering type ATL (sATL) patients, and 21 chronic type ATL (cATL) patients. All blood samples were obtained following written informed consent, and this study was reviewed and approved by

the Institutional Review Board of the Tokyo Medical and Dental University.

Peptides

Peptides used in this study were HLA-A2-restricted CTL epitopes (Tax11-19, LLFGYPVYV)[12] (Hokudo Co., Hokkaido, Japan) and (CMV495-503, NLVPMVATV)[50] (Sigma Aldrich St. Louis, MO), HLA-A11-restricted CTL epitope (Tax88-96, KVLTPPITH)[36] (Hokudo Co) and HLA-A24-restricted CTLs epitopes (Tax301-309, SFHSLHLF)[35] (Hokudo Co) and (CMV341-349, QYDPVAALF)[51] (Sigma Aldrich).

Cell Surface staining

To select samples carrying HLA-A2, -A11, or -A24, whole blood was screened with antibodies for HLA-A2, -A11, and -A24 subtypes (One Lambda, Inc., Los Angeles, CA). FITC-conjugated goat anti-mouse Ig (G +M) (Beckman Coulter Inc., Webster, TX) was used as a secondary antibody. For cell surface staining, whole blood samples were stained with the following fluorochrome-conjugated mouse anti-human mAbs; CD3-FITC, CD8-PE/Cy5, CD8-PerCP/Cy5.5 (RPA-T8, BioLegend), CD27-FITC (O323, BioLegend) CD45RA-FITC (HI 100, BD Biosciences), CD45RA-APC (HI 100, BioLegend), CD69-FITC (FN 50, BioLegend), PD-1-FITC (EH12.2H7, BioLegend), CCR7 (TG8/CCR7, Biolegend).

Tetramer staining

PE-conjugated HLA-A*0201/Tax11-19, HLA-A*1101/Tax88-96, HLA-A*2402/Tax301-309, HLA-A*0201/CMVpp65, HLA-A*2402/CMVpp65 tetramers were purchased from MBL (Nagoya, Japan). Whole blood samples or peripheral blood mononuclear cells (PBMCs) were stained with PE-conjugated Tax/HLA tetramer in conjunction with FITC-conjugated anti-CD3 (UCHT1, BioLegend San Diego, CA), and PE-Cy5-conjugated anti-CD8 monoclonal antibodies (mAbs) (HIT8a, BD Biosciences San Jose, CA). Whole blood samples were lysed and fixed in BD FACS lysing solution (BD Biosciences) before washing the cells. Samples were analyzed on a FACSCalibur (Becton Dickinson, San Jose, CA) and data analyses were performed using CellQuest software (Becton Dickinson).

Tetramer-based IFN- γ flow cytometry

Tetramer-based intracellular IFN- γ flow cytometry was performed as described previously[17], with slight modifications. In brief, PBMCs (2.0×10^5 cells) were incubated with HLA tetramer-PE and anti-CD8-PE/Cy5, washed, and stimulated with 10 μ M antigenic peptide for 6 hrs at 37°C in the presence of brefeldin A (BFA, 10 μ g/ml; Sigma Aldrich). The cells were stained with a

tetramer, permeabilized, and stained with anti-human IFN- γ -FITC (4S.B3, BD Biosciences).

T-cell proliferation

PBMCs (2.0 - 5.0×10^5 cells/well) labeled with carboxy-fluorescein succinimidyl ester (CFSE; Sigma Aldrich) were cultured for 6 days with or without 100 nM antigenic peptide and then stained with Tax/HLA tetramer-PE and anti-CD8-PE/Cy5. In some experiments, PBMCs (2.0×10^5 cells) were cultured for 13 days with 100 nM antigenic peptide and 10 U/ml recombinant human IL-2 (IL-2; Shionogi, Osaka, Japan) in the presence or absence of 0.1 μ g/ml Lipopolysaccharide (LPS; Sigma Aldrich). The cells were then stained with HLA tetramer-PE, anti-CD8-PE/Cy5 and anti-CD3-FITC, and analyzed by flow cytometry.

Quantification of HTLV-1 proviral load

The HTLV-1 proviral load was measured using LightCycler DNA Master SYBR Green 1 (Roche, Mannheim, Germany) with a LightCycler (Roche). Genomic DNA was extracted from PBMCs (2×10^6 cells) using DNeasy Blood & Tissue kits (QIAGEN, Courtaboeuf, France). The primer sets used in this study were as follows: pX2 (5'-CGGATACCCAGTCTACGTGTTTGGAGACTGT-3') and pX3 (5'-GAGCCGATAACGCGTCCATCGATGGGTCC-3') for HTLV-1 pX, and B-globin (5'-ACA-CAACTGTGTTCACTAGC-3') and α B-globin (5'-CAACTTCATCCACGTTTACC-3') for β -globin. The proviral load was calculated as: [(copy number of pX)/(copy number of β -globin/2)] \times 1000. HTLV-1 proviral loads in some of the PBMC samples were measured by the Group of Joint Study on Predisposing Factors of ATL Development (JSPFAD, Japan) as described previously [20].

CD107a mobilization assay

PBMCs were stained with Tax/HLA tetramers-PE and anti-CD8-PE/Cy5, washed, and stimulated with 10 μ M antigenic peptide for 6 hrs at 37°C in the presence of mouse anti-human CD107a-PerCP/Cy5.5 (H4A3, Biolegend) or mouse IgG₁-PerCP/Cy5.5 (MOPC-21, Biolegend). BFA (10 μ g/ml) was added 1 hr after incubation was started. The cells were then collected and stained with an HLA tetramer.

Depletion of CD8⁺ cells and Detection of HTLV-1 p19

CD8⁺ cells were depleted from PBMCs by negative selection using 10-fold numbers of Dynabeads M-450 CD8 (Invitrogen, Carlsbad, CA), according to the manufacturer's instructions. The PBMCs were adjusted to 1×10^6 cells/ml before depletion, and the resulting CD8⁺ cell-depleted fractions were resuspended in medium with the same initial volume, irrespective of the remaining cell

number. PBMCs (1×10^6 cells/ml) and CD8⁺ cell-depleted PBMCs were cultured for 7 days. HTLV-1 p19 in the supernatants of those PBMCs were measured by HTLV p19 antigen ELISA (RETRO tek, Buffalo, NY).

Statistics

The Mann-Whitney U-test, the unpaired t test, and the Spearman rank correlation test were performed for statistical significance by using the Graphpad Prism software (Graphpad Software). In all cases, two-tailed *P* values less than 0.05 were considered significant.

Additional material

Additional file 1: Tax-specific CD8⁺ T-cells in cATL patients could not proliferate against Tax-peptide stimulation.

(A) CFSE-labeled PBMCs were cultured with or without 100 nM Tax-peptide for 6 days. The number indicates the percentage of tetramer⁺ cells in CD8⁺ T cells (Day 0) or the percentage of dividing (CFSE^{low}) cells in Tax-specific CD8⁺ T-cells (Day 6). In a cATL sample #54, CFSE-labeled PBMCs were cultured in the presence of mouse IgG for other experiment. (B) PBMCs (#224) and CCR4-depleted PBMCs (#280) were cultured for 13 days in the presence of 100 nM Tax-peptide. The number indicates the percentage of tetramer⁺ cells in CD8⁺ T-cells.

Acknowledgments and Funding

This work was supported by a grant from the Ministry of Education, Culture, Sports, Science and Technology in Japan, and a grant for an anticancer project from the Ministry of Health, Labour, and Welfare in Japan.

Author details

¹Department of Immunotherapeutics, Tokyo Medical and Dental University, Tokyo, Japan. ²Department of Hematology, Imamura Bun-in Hospital, Kagoshima, Japan. ³Division of Hematology, Department of Internal Medicine, Kinki University School of Medicine, Osaka, Japan. ⁴Department of Molecular Medical Science, Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki, Japan. ⁵Cancer Centre, University of the Ryukyus Hospital, Okinawa, Japan. ⁶Department of Hematology, National Kyushu Cancer Center, Fukuoka, Japan. ⁷Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka, Japan. ⁸Laboratory of Tumor Cell Biology, Department of Medical Genome Science, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan. ⁹Department of Hematology, Osaka Minami Medical Center, Osaka, Japan.

Authors' contributions

AT carried out immunological and virological analyses, and drafted the manuscript. AH conceived of the study, participated in its design and coordination, and drafted the manuscript. AU, YM, YY, MM, IC, NU, and JO provided clinical samples. YS, YT, AS, and NZ carried out a part of the experiments. TW provided the data on proviral load of some HTLV-1-infected individuals. TM helped to draft the manuscript. MK participated in study design and helped to draft the manuscript. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Received: 16 August 2011 Accepted: 7 December 2011

Published: 7 December 2011

References

1. Hinuma Y, Nagata K, Hanaoka M, Nakai M, Matsumoto T, Kinoshita KI, Shirakawa S, Miyoshi I: Adult T-cell leukemia: antigen in an ATL cell line

- and detection of antibodies to the antigen in human sera. *Proc Natl Acad Sci USA* 1981, **78**:6476-6480.
2. Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC: Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. *Proc Natl Acad Sci USA* 1980, **77**:7415-7419.
 3. de The G, Bomford R: An HTLV-I vaccine: why, how, for whom? *AIDS Res Hum Retroviruses* 1993, **9**:381-386.
 4. Arisawa K, Soda M, Endo S, Kurokawa K, Katamine S, Shimokawa I, Koba T, Takahashi T, Saito H, Doi H, Shirahama S: Evaluation of adult T-cell leukemia/lymphoma incidence and its impact on non-Hodgkin lymphoma incidence in southwestern Japan. *Int J Cancer* 2000, **85**:319-324.
 5. Gessain A, Barin F, Vernant JC, Gout O, Maurs L, Calender A, de The G: Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. *Lancet* 1985, **2**:407-410.
 6. Osame M, Izumo S, Igata A, Matsumoto M, Matsumoto T, Sonoda S, Tara M, Shibata Y: Blood transfusion and HTLV-I associated myelopathy. *Lancet* 1986, **2**:104-105.
 7. Tajima K: The 4th nation-wide study of adult T-cell leukemia/lymphoma (ATL) in Japan: estimates of risk of ATL and its geographical and clinical features. The T- and B-cell Malignancy Study Group. *Int J Cancer* 1990, **45**:237-243.
 8. Uchiyama T, Yodoi J, Sagawa K, Takatsuki K, Uchino H: Adult T-cell leukemia: clinical and hematologic features of 16 cases. *Blood* 1977, **50**:481-492.
 9. Bangham CR: HTLV-1 infection: role of CTL efficiency. *Blood* 2008, **112**:2176-2177.
 10. Jacobson S, Shida H, McFarlin DE, Fauci AS, Koenig S: Circulating CD8+ cytotoxic T lymphocytes specific for HTLV-I pX in patients with HTLV-I associated neurological disease. *Nature* 1990, **348**:245-248.
 11. Bieganowska K, Hollsberg P, Buckle GJ, Lim DG, Greten TF, Schneck J, Altman JD, Jacobson S, Ledis SL, Hanchard B, Chin J, Morgan O, Roth PA, Hafler DA: Direct analysis of viral-specific CD8+ T cells with soluble HLA-A2/Tax11-19 tetramer complexes in patients with human T cell lymphotropic virus-associated myelopathy. *J Immunol* 1999, **162**:1765-1771.
 12. Kannagi M, Shida H, Igarashi H, Kuruma K, Murai H, Aono Y, Maruyama I, Osame M, Hattori T, Inoko H, et al: Target epitope in the Tax protein of human T-cell leukemia virus type I recognized by class I major histocompatibility complex-restricted cytotoxic T cells. *J Virol* 1992, **66**:2928-2933.
 13. Parker CE, Daenke S, Nightingale S, Bangham CR: Activated, HTLV-1-specific cytotoxic T-lymphocytes are found in healthy seropositives as well as in patients with tropical spastic paraparesis. *Virology* 1992, **188**:628-636.
 14. Parker CE, Nightingale S, Taylor GP, Weber J, Bangham CR: Circulating anti-Tax cytotoxic T lymphocytes from human T-cell leukemia virus type I-infected people, with and without tropical spastic paraparesis, recognize multiple epitopes simultaneously. *J Virol* 1994, **68**:2860-2868.
 15. Uchiyama T: Human T cell leukemia virus type I (HTLV-I) and human diseases. *Annu Rev Immunol* 1997, **15**:15-37.
 16. Arnulf B, Thorel M, Poirot Y, Tamouza R, Boulanger E, Jaccard A, Oksenhendler E, Hermine O, Pique C: Loss of the ex vivo but not the reinducible CD8+ T-cell response to Tax in human T-cell leukemia virus type 1-infected patients with adult T-cell leukemia/lymphoma. *Leukemia* 2004, **18**:126-132.
 17. Kozako T, Arima N, Toji S, Masamoto I, Akimoto M, Hamada H, Che XF, Fujiwara H, Matsushita K, Tokunaga M, Haraguchi K, Uozumi K, Suzuki S, Takezaki T, Sonoda S: Reduced frequency, diversity, and function of human T cell leukemia virus type 1-specific CD8+ T cell in adult T cell leukemia patients. *J Immunol* 2006, **177**:5718-5726.
 18. Chen S, Ishii N, Ine S, Ikeda S, Fujimura T, Ndhlovu LC, Soroosh P, Tada K, Harigae H, Kameoka J, Kasai N, Sasaki T, Sugamura K: Regulatory T cell-like activity of Foxp3+ adult T cell leukemia cells. *Int Immunol* 2006, **18**:269-277.
 19. Hishizawa M, Imada K, Kitawaki T, Ueda M, Kadowaki N, Uchiyama T: Depletion and impaired interferon-alpha-producing capacity of blood plasmacytoid dendritic cells in human T-cell leukaemia virus type I-infected individuals. *Br J Haematol* 2004, **125**:568-575.
 20. Shimizu Y, Takamori A, Utsunomiya A, Kurimura M, Yamano Y, Hishizawa M, Hasegawa A, Kondo F, Kurihara K, Harashima N, Watanabe T, Okamura J, Masuda T, Kannagi M: Impaired Tax-specific T-cell responses with insufficient control of HTLV-1 in a subgroup of individuals at asymptomatic and smoldering stages. *Cancer Sci* 2009, **100**:481-489.
 21. Gruener NH, Lechner F, Jung MC, Diepolder H, Gerlach T, Lauer G, Walker B, Sullivan J, Phillips R, Pape GR, Klenerman P: Sustained dysfunction of antiviral CD8+ T lymphocytes after infection with hepatitis C virus. *J Virol* 2001, **75**:5550-5558.
 22. Klenerman P, Hill A: T cells and viral persistence: lessons from diverse infections. *Nat Immunol* 2005, **6**:873-879.
 23. Kostense S, Vandenberghe K, Joling J, Van Baarle D, Nanlohy N, Manting E, Miedema F: Persistent numbers of tetramer+ CD8(+) T cells, but loss of interferon-gamma+ HIV-specific T cells during progression to AIDS. *Blood* 2002, **99**:2505-2511.
 24. Shankar P, Russo M, Harnisch B, Patterson M, Skolnik P, Lieberman J: Impaired function of circulating HIV-specific CD8(+) T cells in chronic human immunodeficiency virus infection. *Blood* 2000, **96**:3094-3101.
 25. Wherry EJ, Blattman JN, Murali-Krishna K, van der Most R, Ahmed R: Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. *J Virol* 2003, **77**:4911-4927.
 26. Zajac AJ, Blattman JN, Murali-Krishna K, Sourdive DJ, Suresh M, Altman JD, Ahmed R: Viral immune evasion due to persistence of activated T cells without effector function. *J Exp Med* 1998, **188**:2205-2213.
 27. Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, Reddy S, Mackey EW, Miller JD, Leslie AJ, DePierres C, Mncube Z, Duraiswamy J, Zhu B, Eichbaum Q, Altfield M, Wherry EJ, Coovadia HM, Goulder PJ, Klenerman P, Ahmed R, Freeman GJ, Walker BD: PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. *Nature* 2006, **443**:350-354.
 28. Radziejewicz H, Ibegbu CC, Fernandez ML, Workowski KA, Obideen K, Wehbi M, Hanson HL, Steinberg JP, Masopust D, Wherry EJ, Altman JD, Rouse BT, Freeman GJ, Masopust D, Zhu B, Allison JP, Grakoui A: Liver-infiltrating lymphocytes in chronic human hepatitis C virus infection display an exhausted phenotype with high levels of PD-1 and low levels of CD127 expression. *J Virol* 2007, **81**:2545-2553.
 29. Zhang JY, Zhang Z, Wang X, Fu JL, Yao J, Jiao Y, Chen L, Zhang H, Wei J, Jin L, Shi M, Gao GF, Wu H, Wang FS: PD-1 up-regulation is correlated with HIV-specific memory CD8+ T-cell exhaustion in typical progressors but not in long-term nonprogressors. *Blood* 2007, **109**:4671-4678.
 30. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, Freeman GJ, Ahmed R: Restoring function in exhausted CD8 T cells during chronic viral infection. *Nature* 2006, **439**:682-687.
 31. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC, Horton HF, Fouser L, Carter L, Ling V, Bowman MR, Carreno BM, Collins M, Wood CR, Honjo T: Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. *J Exp Med* 2000, **192**:1027-1034.
 32. Kozako T, Yoshimitsu M, Fujiwara H, Masamoto I, Horai S, White Y, Akimoto M, Suzuki S, Matsushita K, Uozumi K, Tei C, Arima N: PD-1/PD-L1 expression in human T-cell leukemia virus type 1 carriers and adult T-cell leukemia/lymphoma patients. *Leukemia* 2009, **23**:375-382.
 33. van Lier RA, ten Berge IJ, Gamadia LE: Human CD8(+) T-cell differentiation in response to viruses. *Nat Rev Immunol* 2003, **3**:931-939.
 34. Johnson-Nuroth JM, Graber J, Yao K, Jacobson S, Calabrese PA: Memory lineage relationships in HTLV-1-specific CD8+ cytotoxic T cells. *J Neuroimmunol* 2006, **176**:115-124.
 35. Harashima N, Kurihara K, Utsunomiya A, Tanosaki R, Hanabuchi S, Masuda M, Ohashi T, Fukui F, Hasegawa A, Masuda T, Takaue Y, Okamura J, Kannagi M: Graft-versus-Tax response in adult T-cell leukemia patients after hematopoietic stem cell transplantation. *Cancer Res* 2004, **64**:391-399.
 36. Harashima N, Tanosaki R, Shimizu Y, Kurihara K, Masuda T, Okamura J, Kannagi M: Identification of two new HLA-A*1101-restricted tax epitopes recognized by cytotoxic T lymphocytes in an adult T-cell leukemia patient after hematopoietic stem cell transplantation. *J Virol* 2005, **79**:10088-10092.
 37. Elovaara I, Koenig S, Brewah AY, Woods RM, Lehky T, Jacobson S: High human T cell lymphotropic virus type 1 (HTLV-1)-specific precursor

- cytotoxic T lymphocyte frequencies in patients with HTLV-1-associated neurological disease. *J Exp Med* 1993, **177**:1567-1573.
38. Hanon E, Hall S, Taylor GP, Saito M, Davis R, Tanaka Y, Usuku K, Osame M, Weber JN, Bangham CR: **Abundant tax protein expression in CD4+ T cells infected with human T-cell lymphotropic virus type I (HTLV-I) is prevented by cytotoxic T lymphocytes.** *Blood* 2000, **95**:1386-1392.
 39. Sakai JA, Nagai M, Brennan MB, Mora CA, Jacobson S: **In vitro spontaneous lymphoproliferation in patients with human T-cell lymphotropic virus type I-associated neurologic disease: predominant expansion of CD8+ T cells.** *Blood* 2001, **98**:1506-1511.
 40. Yoshie O, Fujisawa R, Nakayama T, Harasawa H, Tago H, Izawa D, Hieshima K, Tatsumi Y, Matsushima K, Hasegawa H, Kanamaru A, Kamihira S, Yamada Y: **Frequent expression of CCR4 in adult T-cell leukemia and human T-cell leukemia virus type 1-transformed T cells.** *Blood* 2002, **99**:1505-1511.
 41. Betts MR, Brenchley JM, Price DA, De Rosa SC, Douek DC, Roederer M, Koup RA: **Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation.** *J Immunol Methods* 2003, **281**:65-78.
 42. Appay V, Dunbar PR, Callan M, Klenerman P, Gillespie GM, Papagno L, Ogg GS, King A, Lechner F, Spina CA, Little S, Havlir DV, Richman DD, Gruener N, Pape G, Waters A, Easterbrook P, Salio M, Cerundolo V, McMichael AJ, Rowland-Jones SL: **Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections.** *Nat Med* 2002, **8**:379-385.
 43. Klebanoff CA, Gattinoni L, Restifo NP: **CD8+ T-cell memory in tumor immunology and immunotherapy.** *Immunol Rev* 2006, **211**:214-224.
 44. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A: **Two subsets of memory T lymphocytes with distinct homing potentials and effector functions.** *Nature* 1999, **401**:708-712.
 45. Wherry EJ, Barber DL, Kaech SM, Blattman JN, Ahmed R: **Antigen-independent memory CD8 T cells do not develop during chronic viral infection.** *Proc Natl Acad Sci USA* 2004, **101**:16004-16009.
 46. Radoja S, Saio M, Schaefer D, Koneru M, Vukmanovic S, Frey AB: **CD8(+) tumor-infiltrating T cells are deficient in perforin-mediated cytolytic activity due to defective microtubule-organizing center mobilization and lytic granule exocytosis.** *J Immunol* 2001, **167**:5042-5051.
 47. Champagne P, Ogg GS, King AS, Knabenhans C, Ellefsen K, Nobile M, Appay V, Rizzardi GP, Fleury S, Lipp M, Forster R, Rowland-Jones S, Sekaly RP, McMichael AJ, Pantaleo G: **Skewed maturation of memory HIV-specific CD8 T lymphocytes.** *Nature* 2001, **410**:106-111.
 48. Penna A, Pilli M, Zerbini A, Orlandini A, Mezzadri S, Sacchelli L, Missale G, Ferrari C: **Dysfunction and functional restoration of HCV-specific CD8 responses in chronic hepatitis C virus infection.** *Hepatology* 2007, **45**:588-601.
 49. Yi JS, Cox MA, Zajac AJ: **T-cell exhaustion: characteristics, causes and conversion.** *Immunology* 2010, **129**:474-481.
 50. Wills MR, Carmichael AJ, Mynard K, Jin X, Weekes MP, Plachter B, Sissons JG: **The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL.** *J Virol* 1996, **70**:7569-7579.
 51. Kuzushima K, Hayashi N, Kimura H, Tsurumi T: **Efficient identification of HLA-A*2402-restricted cytomegalovirus-specific CD8(+) T-cell epitopes by a computer algorithm and an enzyme-linked immunospot assay.** *Blood* 2001, **98**:1872-1881.

doi:10.1186/1742-4690-8-100

Cite this article as: Takamori *et al.*: Functional impairment of Tax-specific but not cytomegalovirus-specific CD8+ T lymphocytes in a minor population of asymptomatic human T-cell leukemia virus type 1-carriers. *Retrovirology* 2011 **8**:100.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit



厚生労働科学研究費補助金
がん臨床研究事業

「成人T細胞性白血病(ATL)の根治を目指した細胞療法の確立
およびそのHTLV-1抑制メカニズムの解明に関する研究」
(平成23年度 総括・分担研究報告書)

発行日 平成24年3月

発行 国立病院機構九州がんセンター

福岡市南区野多目3-1-1 (〒811-1395)

TEL 092 (541) 3231

FAX 092 (551) 4585

<http://www.ia-nkcc.jp/>

印刷

陽文社印刷株式会社

〒815-0082 福岡市南区大楠2丁目4番10号
TEL (092)522-0081 FAX (092)522-0273

